应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BNTX BioNTech SE
盘前交易 04-19 05:07:48 EDT
86.17
-0.23
-0.27%
最高
86.77
最低
85.61
成交量
57.86万
今开
85.67
昨收
86.40
日振幅
1.35%
总市值
204.85亿
流通市值
74.73亿
总股本
2.38亿
成交额
4,981万
换手率
0.67%
流通股本
8,672万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
HC Wainwright & Co.:重申BioNTech(BNTX.US)评级,由买入调整至买入评级, 目标价107.00美元。
智通财经 · 04-17 18:35
HC Wainwright & Co.:重申BioNTech(BNTX.US)评级,由买入调整至买入评级, 目标价107.00美元。
药明生物2023年业绩稳健增长
美通社 · 03-26
药明生物2023年业绩稳健增长
更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知
Reuters · 03-25
更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知
盈利暴跌后,BioNTech 寄希望于癌症药物的上市
Reuters · 03-20
盈利暴跌后,BioNTech 寄希望于癌症药物的上市
“复必泰”开发商BioNTech(BNTX.US)加入新加坡BioPIPS联盟
阿斯达克财经 · 03-18
“复必泰”开发商BioNTech(BNTX.US)加入新加坡BioPIPS联盟
小菜园赴港IPO:业绩逆势增长 竞争日益加剧
中国经济网 · 03-06
小菜园赴港IPO:业绩逆势增长 竞争日益加剧
Atossa Therapeutics Inc盘中异动 早盘快速下挫6.75%报0.951美元
自选股智能写手 · 02-21
Atossa Therapeutics Inc盘中异动 早盘快速下挫6.75%报0.951美元
医疗设备制造商 West Pharmaceutical 预计全年业绩疲软
Reuters · 02-15
医疗设备制造商 West Pharmaceutical 预计全年业绩疲软
Atossa Therapeutics Inc盘中异动 早盘股价大涨5.15%报1.020美元
自选股智能写手 · 02-14
Atossa Therapeutics Inc盘中异动 早盘股价大涨5.15%报1.020美元
Atossa Therapeutics Inc盘中异动 股价大涨5.80%
自选股智能写手 · 02-12
Atossa Therapeutics Inc盘中异动 股价大涨5.80%
Biontech Se跌0.39% 股价跌破100美元大关
自选股智能写手 · 01-24
Biontech Se跌0.39% 股价跌破100美元大关
Biontech Se涨0.25% 股价突破100美元大关
自选股智能写手 · 01-24
Biontech Se涨0.25% 股价突破100美元大关
Atossa Therapeutics Inc盘中异动 早盘股价大涨5.08%报0.865美元
自选股智能写手 · 01-18
Atossa Therapeutics Inc盘中异动 早盘股价大涨5.08%报0.865美元
先声药业(02096):《新英格兰医学杂志》发表抗新冠创新药先诺欣®治疗轻中度COVID-19成年患者的II/III期临床研究结果
智通财经 · 01-18
先声药业(02096):《新英格兰医学杂志》发表抗新冠创新药先诺欣®治疗轻中度COVID-19成年患者的II/III期临床研究结果
Atossa Therapeutics Inc盘中异动 临近午盘股价大跌5.00%报0.865美元
自选股智能写手 · 01-17
Atossa Therapeutics Inc盘中异动 临近午盘股价大跌5.00%报0.865美元
Biontech Se跌3.64% 股价跌破100美元大关
自选股智能写手 · 01-16
Biontech Se跌3.64% 股价跌破100美元大关
加载更多
公司概况
公司名称:
BioNTech SE
所属市场:
NASDAQ
上市日期:
--
主营业务:
BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学,尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究,开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制,利用各种生物学靶点,利用每位患者免疫系统的力量,解决每位患者潜在疾病的独特分子特征。
发行价格:
--
{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":86.17,"timestamp":1713470400000,"preClose":86.4,"halted":0,"volume":578601,"delay":0,"floatShares":86721000,"shares":237725735,"eps":4.233448,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.23,"latestTime":"04-19 05:07:48 EDT","open":85.67,"high":86.77,"low":85.605,"amount":49808690.033094,"amplitude":0.013484,"askPrice":85.57,"askSize":241,"bidPrice":85.15,"bidSize":47,"shortable":3,"etf":0,"ttmEps":4.233448,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713533400000},"adr":0,"listingDate":1570680000000,"adjPreClose":86.17,"adrRate":1,"postHourTrading":{"tag":"盘后","latestPrice":86.17,"preClose":86.17,"latestTime":"19:45 EDT","volume":17851,"amount":1538249.3,"timestamp":1713483958597},"volumeRatio":0.7054156493387651},"requestUrl":"/m/hq/s/BNTX/","defaultTab":"news","newsList":[{"id":"2428313746","title":"HC Wainwright & Co.:重申BioNTech(BNTX.US)评级,由买入调整至买入评级, 目标价107.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428313746","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428313746?lang=zh_cn&edition=full","pubTime":"2024-04-17 18:35","pubTimestamp":1713350149,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申BioNTech(BNTX.US)评级,由买入调整至买入评级, 目标价107.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171835518b2e894d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171835518b2e894d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422238610","title":"药明生物2023年业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2422238610","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2422238610?lang=zh_cn&edition=full","pubTime":"2024-03-26 22:57","pubTimestamp":1711465020,"startTime":"0","endTime":"0","summary":"2023年业务亮点 尽管新冠疫情后面临严峻的宏观环境挑战,集团凭借独特的CRDMO商业模式和成功实施\"跟随并赢得分子\"战略,依然保持业务稳健增长。截至2023年12月31日,集团包括未完成服务订单和里程碑付款在内的未完成订单总额达206亿美元。临床后期和商业化生产收益增长至人民币77.3亿元,占2023年总收益的45.4%,延续集团临床后期和商业化生产业务加速增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4371111_ZH71111_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422592487","title":"更新 1-BioNTech 因拖欠 COVID 疫苗版税而收到美国机构通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2422592487","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422592487?lang=zh_cn&edition=full","pubTime":"2024-03-25 18:47","pubTimestamp":1711363674,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) (在第 2-3 段增加了细节和背景) 路透社3月25日 - BioNTech 周一称,美国国立卫生研究院已向这家德国公司发出通知,要求其支付与COVID-19疫苗相关的版税和其他款项。BioNTech公司与美国制药巨头辉瑞公司(Pfizer )合作生产的COVID-19疫苗引发了特许权使用费支付纠纷。但该公司表示,它不同意美国国立卫生研究院的立场,并打算对所有违约指控进行抗辩。美国国立卫生研究院的发言人没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420671912","title":"盈利暴跌后,BioNTech 寄希望于癌症药物的上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2420671912","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420671912?lang=zh_cn&edition=full","pubTime":"2024-03-20 18:15","pubTimestamp":1710929704,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社柏林3月20日 - 德国生物技术公司(BioNTech )与辉瑞公司(Pfizer )合作生产的COVID-19疫苗在流感大流行期间被广泛使用。这家总部位于美因茨的公司公布的收入为 38.19 亿欧元,比 2022 年下降了四分之三以上,净利润为 9.303 亿欧元,比上年同期下降了 90%。BioNTech公司在一份声明中表示,2024年的目标收入为25亿至31亿欧元,这主要取决于监管方面的发展和COVID-19疫苗的吸收情况。声明还说,该公司的目标是在 2026 年首次推出肿瘤药物,并在 2030 年之前批准十项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2420490021","title":"“复必泰”开发商BioNTech(BNTX.US)加入新加坡BioPIPS联盟","url":"https://stock-news.laohu8.com/highlight/detail?id=2420490021","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420490021?lang=zh_cn&edition=full","pubTime":"2024-03-18 12:26","pubTimestamp":1710735960,"startTime":"0","endTime":"0","summary":"新加坡科技研究局和新加坡经济发展局今早发表联合公告,指全球免疫疗法公司BioNTech加入新加坡生物制药创新计划联盟,有助于加强当地生物制剂生产领域的生产力和可持续性。现有的联盟成员包括全球制药公司葛兰素史克和赛诺菲,以及新加坡的研究机构和高等教育机构如科研局、新加坡南洋理工大学、新加坡国立大学和新加坡理工大学。在新冠疫情大流行期间,由辉瑞/BioNTech联合开发的“复必泰”新冠疫苗被多国采购,BioNTech声名鹊起。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20231101162245490_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20231101162245490_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1334173/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2417741634","title":"小菜园赴港IPO:业绩逆势增长 竞争日益加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2417741634","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2417741634?lang=zh_cn&edition=full","pubTime":"2024-03-06 07:12","pubTimestamp":1709680320,"startTime":"0","endTime":"0","summary":"《经济参考报》记者注意到,深耕大众便民中式餐饮的小菜园,最近两三年业绩逆势增长。 出乎意料的是,小菜园往绩记录期间主要业绩却实现了超过行业水平的逆势大增。而净利润方面,小菜园近年来的表现更为亮眼。此外,报告期各期,小菜园的毛利率分别为65.5%、66.1%和68.6%,呈持续攀升态势。 谈及行业竞争时,小菜园称,我国餐饮业的激烈竞争可能阻碍公司提升或保持收入及盈利能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-03-06/doc-inamisvu9279593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-03-06/doc-inamisvu9279593.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413277484","title":"Atossa Therapeutics Inc盘中异动 早盘快速下挫6.75%报0.951美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413277484","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413277484?lang=zh_cn&edition=full","pubTime":"2024-02-21 23:41","pubTimestamp":1708530101,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日23时41分,Atossa Therapeutics Inc股票出现波动,股价快速下挫6.75%。Atossa Therapeutics Inc股票所在的生物技术行业中,整体跌幅为0.14%。Atossa Therapeutics Inc公司简介:Atossa Therapeutics Inc 是一家临床阶段的生物制药公司,在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。该公司正在开发的治疗乳腺癌和其他乳腺疾病的药物是 Endoxifen。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221234141861d71dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240221234141861d71dc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411892512","title":"医疗设备制造商 West Pharmaceutical 预计全年业绩疲软","url":"https://stock-news.laohu8.com/highlight/detail?id=2411892512","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411892512?lang=zh_cn&edition=full","pubTime":"2024-02-15 20:09","pubTimestamp":1707998941,"startTime":"0","endTime":"0","summary":"由于 COVID-19 疫苗和相关疗法的需求下降,该公司最近几个季度的销售额受到打击。\"West Pharmaceutical 首席执行官埃里克-格林说:\"2024 年,随着我们对库存管理时机的把握,尤其是对我们最大客户的管理,我们预计有机销售额的增长将有所放缓。West Pharmaceutical 预测 2024 年调整后每股收益在 7.50 美元至 7.75 美元之间,预期为 8.79 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411976585","title":"Atossa Therapeutics Inc盘中异动 早盘股价大涨5.15%报1.020美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411976585","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411976585?lang=zh_cn&edition=full","pubTime":"2024-02-14 23:50","pubTimestamp":1707925832,"startTime":"0","endTime":"0","summary":"北京时间2024年02月14日23时50分,Atossa Therapeutics Inc股票出现异动,股价快速上涨5.15%。Atossa Therapeutics Inc股票所在的生物技术行业中,整体涨幅为0.90%。其相关个股中,Engene Holdings Inc C/Wts 31/10/2028 Cl A、Engene Holdings Inc、Cogent Biosciences Inc涨幅较大,Kintara Therapeutics Inc、Azitra Inc、Transcode Therapeutics Inc较为活跃,换手率分别为53.40%、31.61%、30.30%,振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028 Cl A、Engene Holdings Inc、Renovaro Biosciences Inc,振幅分别为208.62%、51.31%、39.06%。Atossa Therapeutics Inc公司简介:Atossa Therapeutics Inc 是一家临床阶段的生物制药公司,在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214235032861d53e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240214235032861d53e0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2410082830","title":"Atossa Therapeutics Inc盘中异动 股价大涨5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2410082830","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2410082830?lang=zh_cn&edition=full","pubTime":"2024-02-12 22:40","pubTimestamp":1707748851,"startTime":"0","endTime":"0","summary":"北京时间2024年02月12日22时40分,Atossa Therapeutics Inc股票出现波动,股价急速上涨5.80%。Atossa Therapeutics Inc股票所在的生物技术行业中,整体跌幅为0.43%。Atossa Therapeutics Inc公司简介:Atossa Therapeutics Inc 是一家临床阶段的生物制药公司,在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021222405187e6fc70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021222405187e6fc70&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405442271","title":"Biontech Se跌0.39% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2405442271","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2405442271?lang=zh_cn&edition=full","pubTime":"2024-01-24 22:58","pubTimestamp":1706108303,"startTime":"0","endTime":"0","summary":"北京时间2024年01月24日22时58分,Biontech Se股票出现异动,股价大幅下跌0.39%。截至发稿,该股报99.90美元/股,成交量3.4902万股,换手率0.01%,振幅1.07%。Biontech Se股票所在的生物技术行业中,整体跌幅为0.35%。Biontech Se公司简介:BioNTech 是一家总部位于德国的生物技术公司,专注于开发癌症疗法,包括个体化免疫疗法以及COVID-19等传染病疫苗。BioNTech 与多家大型制药公司合作,包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401242258237a3e0b47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401242258237a3e0b47&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405106964","title":"Biontech Se涨0.25% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2405106964","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2405106964?lang=zh_cn&edition=full","pubTime":"2024-01-24 03:11","pubTimestamp":1706037060,"startTime":"0","endTime":"0","summary":"北京时间2024年01月24日03时11分,Biontech Se股票出现波动,股价大幅上涨0.25%。截至发稿,该股报100.06美元/股,成交量36.8513万股,换手率0.16%,振幅1.56%。Biontech Se股票所在的生物技术行业中,整体涨幅为0.25%。Biontech Se公司简介:BioNTech 是一家总部位于德国的生物技术公司,专注于开发癌症疗法,包括个体化免疫疗法以及COVID-19等传染病疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012403110087e67c03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012403110087e67c03&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404536435","title":"Atossa Therapeutics Inc盘中异动 早盘股价大涨5.08%报0.865美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2404536435","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2404536435?lang=zh_cn&edition=full","pubTime":"2024-01-18 22:36","pubTimestamp":1705588606,"startTime":"0","endTime":"0","summary":"北京时间2024年01月18日22时36分,Atossa Therapeutics Inc股票出现异动,股价急速拉升5.08%。Atossa Therapeutics Inc股票所在的生物技术行业中,整体跌幅为0.87%。其相关个股中,Celularity Inc、Biocardia Inc C/Wts 06/08/2024、Apollomics Inc C/Wts 01/04/2028 涨幅较大,Kintara Therapeutics Inc、Transcode Therapeutics Inc、Zyversa Therapeutics Inc较为活跃,换手率分别为56.22%、40.84%、16.87%,振幅较大的相关个股有Celularity Inc、Acelyrin Inc、Transcode Therapeutics Inc,振幅分别为19.38%、17.61%、14.81%。Atossa Therapeutics Inc公司简介:Atossa Therapeutics Inc 是一家临床阶段的生物制药公司,在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011822364687e664d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024011822364687e664d2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2404588204","title":"先声药业(02096):《新英格兰医学杂志》发表抗新冠创新药先诺欣®治疗轻中度COVID-19成年患者的II/III期临床研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2404588204","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2404588204?lang=zh_cn&edition=full","pubTime":"2024-01-18 19:53","pubTimestamp":1705578821,"startTime":"0","endTime":"0","summary":"该研究的成功发表,标志着先诺欣成为首个成功打造完整证据链的国产3CL靶点抗新冠药物。此前,先诺欣临床前、I期、Ib期临床研究结果已在2023年7月至10月间先后于《柳叶刀》子刊、《自然》子刊等知名学术期刊发表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1057642.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2404890144","title":"Atossa Therapeutics Inc盘中异动 临近午盘股价大跌5.00%报0.865美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2404890144","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2404890144?lang=zh_cn&edition=full","pubTime":"2024-01-17 01:00","pubTimestamp":1705424457,"startTime":"0","endTime":"0","summary":"北京时间2024年01月17日01时00分,Atossa Therapeutics Inc股票出现异动,股价急速跳水5.00%。截至发稿,该股报0.865美元/股,成交量13.3254万股,换手率0.11%,振幅3.30%。Atossa Therapeutics Inc股票所在的生物技术行业中,整体跌幅为0.14%。Atossa Therapeutics Inc公司简介:Atossa Therapeutics Inc 是一家临床阶段的生物制药公司,在肿瘤学中未满足的重大医疗需求领域开发专利创新药物。该公司正在开发的治疗乳腺癌和其他乳腺疾病的药物是 Endoxifen。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240117010057790969b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240117010057790969b4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2403189839","title":"Biontech Se跌3.64% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2403189839","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2403189839?lang=zh_cn&edition=full","pubTime":"2024-01-16 22:45","pubTimestamp":1705416316,"startTime":"0","endTime":"0","summary":"北京时间2024年01月16日22时45分,Biontech Se股票出现异动,股价快速下跌3.64%。截至发稿,该股报99.80美元/股,成交量14.2732万股,换手率0.06%,振幅1.36%。Biontech Se股票所在的生物技术行业中,整体跌幅为0.47%。Biontech Se公司简介:BioNTech 是一家总部位于德国的生物技术公司,专注于开发癌症疗法,包括个体化免疫疗法以及COVID-19等传染病疫苗。BioNTech 与多家大型制药公司合作,包括罗氏、礼来、辉瑞、赛诺菲和 Genmab。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240116224516790965ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240116224516790965ce&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.de","stockEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0845},{"period":"3month","weight":-0.1227},{"period":"6month","weight":-0.0521},{"period":"1year","weight":-0.2925},{"period":"ytd","weight":-0.1835}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0314},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.186},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.0509}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学,尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究,开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制,利用各种生物学靶点,利用每位患者免疫系统的力量,解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.036134},{"month":2,"riseRate":0.2,"avgChangeRate":-0.029347},{"month":3,"riseRate":0.8,"avgChangeRate":0.158218},{"month":4,"riseRate":0.2,"avgChangeRate":0.040438},{"month":5,"riseRate":0.75,"avgChangeRate":0.0559},{"month":6,"riseRate":0.75,"avgChangeRate":0.096187},{"month":7,"riseRate":1,"avgChangeRate":0.203321},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066227},{"month":9,"riseRate":0.25,"avgChangeRate":-0.052386},{"month":10,"riseRate":0.75,"avgChangeRate":0.033872},{"month":11,"riseRate":1,"avgChangeRate":0.26222},{"month":12,"riseRate":0.4,"avgChangeRate":-0.023804}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}